Publication date: Jul 30, 2025
A multicenter cohort of patients hospitalized with COVID-19 was examined to consider the impact of comorbid liver disease in general, and alcohol-associated liver disease (ALD) in particular, on short-term outcomes. Data from patients with COVID-19 hospitalized at 21 participating healthcare systems between February 2020 and January 2022 were examined. The analyses used generalized linear mixed model logistic regression including random intercepts to account for clustering within healthcare systems. Among 145,944 patients hospitalized with COVID-19, 7951 (5. 4%) had comorbid liver disease; 1153 (14. 5%) had ALD, and 6798 (85. 5%) had nonalcohol-associated liver disease (NAALD). The presence of liver disease was associated with increased mortality (adjusted odds ratio [aOR] 3. 39, p
| Concepts | Keywords |
|---|---|
| Disease | alcohol use disorder |
| February | cirrhosis |
| Hoboken | mortality |
| Liver |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Ethanol |
| disease | MESH | liver disease |
| disease | MESH | COVID-19 |
| disease | MESH | alcohol use disorder |
| disease | MESH | cirrhosis |